Outcomes and Prognostic Factors of Extensive Stage Small Cell Lung Cancer: A Retrospective Study

Abstract

Introduction

Small cell lung cancer (SCLC) represents about 15% of all lung cancers. Extensive stage (ES) SCLC represents around 60% of diagnosed SCLC cancers. The median survival in untreated ES SCLC is 2 to 4 months and that of treated cases is 8 to 13 months.

Aim and Objectives

This retrospective analysis aims to find out the clinical outcome of patients with ES SCLC and the prognostic factors affecting their survival.

Methods

Details of patients registered in the department of radiation oncology from January 1, 2010 to September 30, 2019 were retrieved from the hospital records. This includes the demographic characteristics, treatment received, toxicity, and follow-up details.

Results

Two-hundred eighty-three patients were included. Median age of presentation was 62 years. Around 97.5% of patients were men. Smokers constitute 94% of all cases. About 86.9% (246 patients) of cases were not alive at the end of the study period. The median estimated overall survival (OS) was 7 months ± 0.47 (95% confidence interval [CI]: 6.026–7.974) and progression-free survival (PFS) was 5 months ± 0.535 (95% CI: 3.952–6.048). Multivariate analysis showed that Eastern Cooperative Oncology Group performance status (ECOG PS), hyponatremia, number of chemotherapy cycles, consolidative radiotherapy (RT) and prophylactic cranial irradiation (PCI) were found to have prognostic effect on OS. Smoking, ECOG PS, number of chemotherapy cycles, consolidative RT, and PCI were found to have prognostic effects on PFS.

Conclusion

There is a difference in OS and PFS patterns of ES SCLC patients among various Indian studies even though the available data is scarce. Our study shows that the OS and PFS of our study population are comparable to other South Indian studies available. PS, serum sodium level, number of chemotherapy cycles, consolidative RT, and PCI were found to be independent prognostic factors for survival of ES SCLC. The identification of these factors will help physicians to tailor treatment.

Keywords

outcome - PCI - prognostic factors - small cell lung cancer

Publikationsverlauf

Artikel online veröffentlicht:
09. Juni 2023

• Reference

• 1 Global Cancer Observatory. Accessed April 12, 2023 at: https://gco.iarc.fr/
• 2 Report of National Cancer Registry Programme 2020. Accessed April 12, 2023 at: https://www.ncdirindia.org/All_Reports/Report_2020/default.aspx
• 3 Zelen M. Keynote address on biostatistics and data retrieval. Cancer Chemother Rep 3 1973; 4 (02) 31-42
• 4 Govindan R, Page N, Morgensztern D. et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 2006; 24 (28) 4539-4544
• 5 Roth BJ, Johnson DH, Einhorn LH. et al. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 1992; 10 (02) 282-291
• 6 Jeremic B, Shibamoto Y, Nikolic N. et al. Role of radiation therapy in the combined-modality treatment of patients with extensive disease small-cell lung cancer: a randomized study. J Clin Oncol 1999; 17 (07) 2092-2099
• 7 Zhu H, Zhou Z, Wang Y. et al. Thoracic radiation therapy improves the overall survival of patients with extensive-stage small cell lung cancer with distant metastasis. Cancer 2011; 117 (23) 5423-5431
• 8 Slotman B, Faivre-Finn C, Kramer G. et al; EORTC Radiation Oncology Group and Lung Cancer Group. Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med 2007; 357 (07) 664-672
• 9 Cappuzzo F, Le Pechoux C, Le Chevalier T. Small cell lung cancer. In: Vokes EE, Golomb HM. eds. Oncologic Therapies. Berlin, Heidelberg: Springer Berlin Heidelberg; 2003: 407-414
• 10 van Meerbeeck JP, Fennell DA, De Ruysscher DKM. Small-cell lung cancer. Lancet 2011; 378 (9804): 1741-1755
• 11 Fukui T, Itabashi M, Ishihara M. et al. Prognostic factors affecting the risk of thoracic progression in extensive-stage small cell lung cancer. BMC Cancer 2016; 16: 197
• 12 Regional Cancer Centre. RCC, Thiruvananthapuram, Kerala, India. Accessed April 12, 2023 at: http://www.rcctvm.gov.in/
• 13 Unalmış D, Yasar Z, Buyuksirin M. et al. Clinical features and outcomes of patients with small cell lung carcinoma: retrospective analysis. Acta Medica Anatolia 2015; 3: 47
• 14 Wahba HA, El-Hadaad HA, Anter AH. et al. Outcomes and prognostic factors of small cell lung cancer: a retrospective study. Adv Lung Cancer (Irvine) 2018; 07: 21-31
• 15 Tsao AS, Liu D, Lee JJ, Spitz M, Hong WK. Smoking affects treatment outcome in patients with advanced nonsmall cell lung cancer. Cancer 2006; 106 (11) 2428-2436
• 16 Osterlind K, Andersen PK. Prognostic factors in small cell lung cancer: multivariate model based on 778 patients treated with chemotherapy with or without irradiation. Cancer Res 1986; 46 (08) 4189-4194
• 17 De Almeida SB, Vitorino M, Gonçalves S. MO01.44 prognostic factors in extensive-stage small cell lung cancer (SCLC). J Thorac Oncol 2021; 16: S34-S35
• 18 Sculier J-P, Chansky K, Crowley JJ. et al. The impact of additional prognostic factors on survival and their relationship with the anatomical extent of disease expressed by the 6th Edition of the TNM Classification of Malignant Tumors and the proposals for the 7th Edition. J Thorac Oncol 2008; 3: 457-466
• 19 Gao H, Dang Y, Qi T, Huang S, Zhang X. Mining prognostic factors of extensive-stage small-cell lung cancer patients using nomogram model. Medicine (Baltimore) 2020; 99 (33) e21798
• 20 Hong X, Xu Q, Yang Z. et al. The value of prognostic factors in Chinese patients with small cell lung cancer: a retrospective study of 999 patients. Clin Respir J 2018; 12 (02) 433-447
• 21 Athey VL, Walters SJ, Rogers TK. Symptoms at lung cancer diagnosis are associated with major differences in prognosis. Thorax 2018; 73 (12) 1177-1181
• 22 Shojaee S, Singh I, Solsky I, Nana-Sinkam P. Malignant pleural effusion at presentation in patients with small-cell lung cancer. Respiration 2019; 98 (03) 198-202
• 23 Wang X, Liu M, Zhang L, Ma K. Syndrome of inappropriate antidiuretic hormone secretion: a poor prognosis in small-cell lung cancer. Arch Med Res 2016; 47 (01) 19-24
• 24 Nakazawa K, Kurishima K, Tamura T. et al. Specific organ metastases and survival in small cell lung cancer. Oncol Lett 2012; 4 (04) 617-620
• 25 Tas F, Aydiner A, Topuz E, Camlica H, Saip P, Eralp Y. Factors influencing the distribution of metastases and survival in extensive disease small cell lung cancer. Acta Oncol 1999; 38 (08) 1011-1015
• 26 Mohan A, Goyal A, Singh P. et al. Survival in small cell lung cancer in India: prognostic utility of clinical features, laboratory parameters and response to treatment. Indian J Cancer 2006; 43 (02) 67-74
• 27 Kawahara M, Fukuoka M, Saijo N. et al. Prognostic factors and prognostic staging system for small cell lung cancer. Jpn J Clin Oncol 1997; 27 (03) 158-165
• 28 Wang L, Dou X, Liu T, Lu W, Ma Y, Yang Y. Tumor size and lymph node metastasis are prognostic markers of small cell lung cancer in a Chinese population. Medicine (Baltimore) 2018; 97 (31) e11712
• 29 Sallam M, Wong H, Escriu C. Treatment beyond four cycles of first line Platinum and Etoposide chemotherapy in real-life patients with stage IV Small Cell Lung Cancer: a retrospective study of the Merseyside and Cheshire Cancer network. BMC Pulm Med 2019; 19 (01) 195
• 30 Veslemes M, Polyzos A, Latsi P. et al. Optimal duration of chemotherapy in small cell lung cancer: a randomized study of 4 versus 6 cycles of cisplatin-etoposide. J Chemother 1998; 10 (02) 136-140
• 31 Han J, Fu C, Li B. Clinical outcomes of extensive-stage small cell lung cancer patients treated with thoracic radiotherapy at different times and fractionations. Radiat Oncol 2021; 16 (01) 47
• 32 Yin X, Yan D, Qiu M, Huang L, Yan SX. Prophylactic cranial irradiation in small cell lung cancer: a systematic review and meta-analysis. BMC Cancer 2019; 19 (01) 95
• 33 Sharma S, McMillan MT, Doucette A. et al. Effect of prophylactic cranial irradiation on overall survival in metastatic small-cell lung cancer: a propensity score-matched analysis. Clin Lung Cancer 2018; 19 (03) 260-269.e3
• 34 Albain KS, Crowley JJ, LeBlanc M, Livingston RB. Determinants of improved outcome in small-cell lung cancer: an analysis of the 2,580-patient Southwest Oncology Group data base. J Clin Oncol 1990; 8 (09) 1563-1574
• 35 Ma X, Zhang Z, Chen X. et al. Prognostic factor analysis of patients with small cell lung cancer: real-world data from 988 patients. Thorac Cancer 2021; 12 (12) 1841-1850
• 36 Foster NR, Qi Y, Shi Q. et al. Tumor response and progression-free survival as potential surrogate endpoints for overall survival in extensive stage small-cell lung cancer: findings on the basis of North Central Cancer Treatment Group trials. Cancer 2011; 117 (06) 1262-1271
• 37 Murali AN, Radhakrishnan V, Ganesan TS. et al. Outcomes in lung cancer: 9-year experience from a tertiary cancer center in India. J Glob Oncol 2017; 3 (05) 459-468
• 38 Puligundla KC, Gundeti S, Maddali LS. et al. 96P: Small cell lung cancer: Prognostic factors and outcome at a tertiary care centre in South India. J Thorac Oncol 2016; 11: S98
• 39 Julka PK, Sharma DN, Madan R. et al. Patterns of care and survival among small cell lung cancer patients: experience from a tertiary center in India. J Egypt Natl Canc Inst 2017; 29 (01) 47-51
• 40 Ganguly S, Biswas B, Bhattacharjee S. et al. Clinicopathological characteristics and treatment outcome in small cell lung cancer: a single institutional experience from India. Lung India 2020; 37 (02) 134-139